ONCAlert | 2017 NANETS Symposium

Results for Durvalumab in the Second-Line Treatment of NSCLC

Martin Gutierrez, MD
Published Online:1:50 PM, Thu July 13, 2017

Martin Gutierrez, MD, director, drug discovery/phase I unit, medical oncologist, thoracic and gastrointestinal oncology, John Theurer Cancer Center, discusses results for durvalumab (Imfinzi) for the treatment of non-small cell lung cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.